Each January, San Francisco hosts what the global biopharmaceutical, medical device, and healthcare technology sectors deem "the most important week of the year"—JPMorgan Healthcare Week (JPM Week).
At the 2026 JPMorgan Healthcare Conference, discussions on licensing deals and pricing policies are drawing significant attention. The focus is centered on licensing agreements rather than large-scale mergers and acquisitions, alongside drug pricing policies, which could have implications for AbbVie (ABBV), Novartis (NVS), Revolution Medicines (RVMD), and Abivax (ABVX).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments